Patients with NAFLD and NASH have increased plasma bile acids, mainly conjugated bile acids such as glycocholate and taurocholate, two known substrates of NTCP [27,28,29,30,31]. The gene discussed is SLC10A1; the disease is metabolic dysfunction-associated steatotic liver disease.